NAMD Letter to Senate Finance on Prescription Drug Pricing and Expenditures

NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these drugs on the Medicaid program.

Read full letter.

Comments are closed.